Clinical implications of new insights into the regulation of bone resorption;Klinische implicaties van nieuwe inzichten in de regulatie van botafbraak

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 30, 2005, Pages 1664-1667

  Lems, W F ^a,b   Bijlsma, J W J ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

BONE METASTASIS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG COST; FRACTURE REDUCTION; HUMAN; MULTIPLE MYELOMA; OSTEOBLAST; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RHEUMATOID ARTHRITIS;

BONE DISEASES; BONE RESORPTION; CARRIER PROTEINS; GLYCOPROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; OSTEOBLASTS; OSTEOPROTEGERIN; PHOSPHONIC ACIDS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 23844480797     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgers T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
2. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292:490-5.
3. Favus MJ, Christakos S, Holick MF, Kleerkoper M, Lane N, Langman CB. American Society of Bone and Mineral Research. Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2003.
4. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
5. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003;111:1221-30.
6. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999;140: 4367-70.
7. Viereck V, Grundker C, Blaschke S, Niederkleine B, Siggelkow H, Frosch KH, et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukine-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab 2003;88:4206-13.
8. Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000;43:2143-51.
9. Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 2003;48:2042-51.
10. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000;192:463-74.
11. Jono S, Ikary Y, Shioi A, Mori K, Miki T, Hara K, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002;106:1192-4.
12. Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002;87:4470-5.
13. Mezquita-Raya P, de la Higuera M, Garcia DF, Alonso G, Ruiz-Requena ME, de Dios Luna J. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int [ter perse].
14. Lems WF, Jacobs JWG, Netelenbos JC, Dijkmans BAG, Bijlsma JWJ. Medicamenteuze preventie van osteoporose bij gebruik van corticosteroïden. Ned Tijdschr Geneeskd 1998;142:1904-8.
15. Sasaki N, Kusano E, Ando Y, Yano K, Tsuda E, Asano Y. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. Nephrol Dial Transplant 2001;16:479-82.
16. Vanderborght A, Linsen L, Thewissen M, Geusens P, Raus J, Stinissen P. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. J Rheumatol 2004;31:1483-90.
17. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98: 3527-33.
18. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003;102:1064-9.
19. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002;46: 1744-53.
20. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001;16:348-60.
21. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003;97(3 Suppl):887-92.
22. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1059-66.
23. McClung MR, Lewiecki EM, Bolognese MA, Woodson G, Moffett A, Peacock M, et al. AMG 162 increases BMD within 1 month in post-menopausal women with low BMD [abstract]. J Bone Miner Res 2004;19:1072.